Navigation Links
Phase 1b/2a Program Commences for RVX-208
Date:8/25/2008

TSX Exchange Symbol: RVX

CALGARY, Aug. 25 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan.

"We are very excited about moving forward into this important 28-day study with RVX-208. Our previous clinical study demonstrated that RVX-208 was safe, tolerable and had favorable pharmacokinetics," stated Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix. "This trial will continue to examine safety and tolerance as well it is a proof of principle study for ApoA-I production and HDL functionality. Approximately half of the subjects will have low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease," added Dr. Gordon.

"The ensuing Phase 1b/2a study comprises several novel facets to expedite the clinical process for RVX-208 and its eventual registration as a drug," stated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey further confirmed, "Along with the required regulatory provisions that must be addressed such as safety, tolerance and pharmacokinetics, the study also will measure key reverse cholesterol transport markers which RVX-208 impacts. These are exclusive favorable features that make this drug unique among its competitors."

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.

About Resverlogix Corp.

Resverlogix Corp. is a leadin
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
2. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
3. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
4. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
5. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
6. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
7. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Winston-Salem, NC and Rocky Mount, NC (PRWEB) September 02, ... (PMG) announced today the establishment of its 11th clinical ... 1, PMG Research has assumed ownership and operation of ... in Rocky Mount, NC, further expanding PMG’s presence in ... to an additional 130,000 patients. For the patients in ...
(Date:9/1/2014)... 2014 Reportlinker.com announces that a new ... India Solid Waste Management Vehicles Market ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In India ... bodies responsible for complete handling and regulation of ... around 135,000 MT solid waste is generated daily ...
(Date:8/31/2014)... Available spectra is similar for all L-series ... of a wide range of plants. The spectra ... patented and pending wide spectrum technology. The single ... applications in contrast to growth spectra made from ... a large variety of differently sized and shaped ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
Breaking Biology Technology:PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... ATHENS, Ga., March 31 ArunA Biomedical, Inc., a ... today that it has been awarded a Department of ... human stem cell technology. (Logo: ... a human embryonic stem cell derived cellular model for ...
... , - Books Authored by ... Two of the biggest names in health care publishing, ... agreement to,co-publish International Classification of Diseases, Ninth Revision, Clinical,Modification (ICD-9-CM) ... Buck, beginning with the 2010 editions, in fall 2009. , ...
... 31 Viroblock SA has announced,today that ... nasal spray,formulation is active against human influenza. ... inactivates enveloped,viruses during the extra-cellular phase, by ... The two pre-clinical studies ...
Cached Biology Technology:ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security 2The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books 2The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books 3Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray 2
(Date:9/1/2014)... AM EDT) It may be possible to train ... higher-calorie foods, according to new research by scientists at ... Aging (USDA HNRCA) at Tufts University and at Massachusetts ... Nutrition & Diabetes , a brain scan study in ... to reverse the addictive power of unhealthy food while ...
(Date:9/1/2014)... About 50 years ago, electron microscopy revealed the ... move around and disappear. But scientists still don,t know ... collections of proteins are believed to be crucial to ... a new approach to disease treatment., In the ... a call to investigators from various backgrounds, from biophysics ...
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
Breaking Biology News(10 mins):Training your brain to prefer healthy foods 2Scientists call for investigation of mysterious cloud-like collections in cells 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
... damage, for example as a result of exposure to ionizing ... damage or program themselves for death, a process called apoptosis. ... as it is remarkable, involving what might be described metaphorically ... DNA packed tightly in the cell nucleus. In intricate ...
... prevalence of a certain form of drug-resistant ... surpassed that of two other common antimicrobial-resistant ... a study conducted by researchers at Hebrew ... long-term care facilities are one of the ...
... offshore drilling last year, federal lawmakers have grappled with the ... allow oil, wave and wind energy development, while sustainably managing ... A new policy paper, published April 10 in Science ... establishing a public trust doctrine for federal waters could be ...
Cached Biology News:CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 2CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 4Study finds multidrug-resistant gram-negative bacteria high in long-term care 2Public trust doctrine could aid management of US oceans 2Public trust doctrine could aid management of US oceans 3
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
Similar to proteasome (prosome, macropain) 26S subunit, ATPase, 1 Antigen: Recombinant Protein...
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
...
Biology Products: